The following statement is being issued by Levi & Korsinsky, LLP:
TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED
COMMON STOCK OF PHARMACYCLICS INC. PRIOR TO
MARCH 4, 2015 AND CONTINUE TO HOLD SUCH SHARES.
YOU ARE HEREBY NOTIFIED that Levi & Korsinsky, LLP has commenced
an investigation into the fairness of the sale of
Pharmacyclics Inc. (“Pharmacyclics”) (Nasdaq: PCYC). Click
here to learn more about the action: http://zlk.9nl.com/pharmacyclics-pcyc.
There is no cost or obligation to you.
The Board of Directors of Pharmacyclics agreed to sell the company to
AbbVie (NYSE: ABBV). Under the terms of the transaction,
Pharmacyclics shareholders will receive $261.25 per share in cash and
stock. The investigation concerns whether the Board of
Pharmacyclics breached their fiduciary duties to stockholders by failing
to adequately shop the Company before agreeing to enter into this
transaction, and whether AbbVie is underpaying for Pharmacyclics
shares.
If you own Pharmacyclics common stock and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/pharmacyclics-pcyc.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Copyright Business Wire 2015